Reports
Publicerat: 2019-08-30 08:30:00
FluoGuide today publishes its interim report for the period January - June 2019
Andreas Kjær, responsible for research of FluoGuide comments: "I am very pleased that promising data on the benefit of FG001 in glioblastoma and pancreatic cancer have been selected for presentation at WMIC, an important society within molecular imaging and surgical guidance. Optical targeting of uPAR is likely to become of benefit to patients and surgeons in several cancer indications and this presentation is an important event to highlight the technology’s potential." Morten Albrechtsen, CEO of FluoGuide comments: "We are very pleased with the successful IPO and to see that the potential of uPAR as target for guiding cancer surgery is unfolding earlier than expected as exemplified with the two presentations at WMIC” Result for second quarter 2019 (April – June): *) Result per share (DKK per share): Operating result divided by the average number of shares during the period. Total number of shares as of 30 June 2019, amounted to 7,224,274 shares (105,500). The total number of shares at the beginning of the period amounted to 4,000,000 shares (105,500). The average number of shares for the second quarter 2019 was 6,651,070 (105,500). The Company was converted to a public company and increased its shares in Q2 2019. FluoGuide did not have any revenue for the reported period, and the Company had a negative result. This follows the plan outlined in the IPO prospectus and is conventional from an early stage life science company. The financial result is as expected, and it is the Board’s opinion that FluoGuide has a relatively short time to market compared to many other life science companies. The Company is continuing its work on preparing FG001 for the first clinical study to be able to improve the outcome for patients with cancer undergoing surgery. Highlights during Q2 Highlights after Q2 __________________________________________________________________________________ About FluoGuide
**) Solidity: Totale quity divided by total capital and liability.
For further information about FluoGuide, please contact:
Morten Albrechtsen, CEO
M: +45 24 25 62 66
ma@fluoguide.com
FluoGuide A/S provides solutions for maximizing surgical outcome through intelligent targeting. FluoGuide’s first product, FG001, improves precision in cancer surgery by lighting up the cancer and its invasive growth into the surrounding tissue. FG001 is made of a cancer targeting molecule linked to a fluorophore. The FluoGuide products is expected to reduce the suffering of patients and increase the likelihood of cure. They can also reduce costs for the health care system and thus benefit society. FluoGuide focuses on demonstrating the effect of FG001 in patients by conducting a human proof-of-concept clinical trial. The potential of FluoGuide goes beyond FG001 and cancer surgery. FluoGuide is listed on Spotlight Stock Market (ticker: FLUO)